A Phase 2 interventional study of Placebo and AC-201 in Gout Flares, sponsored by TWi Biotechnology, Inc.. Completed at 1 site in Taiwan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-05-22.
Sponsored by TWi Biotechnology, Inc. · Phase 2, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hyperuricemia with a site in Taiwan — 1 open to participants now, 1 under way, none of them phase 3. Hyperuricemia · Taiwan.
Among the 14 studies in Hyperuricemia with a site in Taiwan, this one is one of 2 that started in 2013, is one of 4 in phase 2, and was the 3rd registered.
240 studies on the registry are indexed under Hyperuricemia; 44 are open to participants now.
Browse Hyperuricemia studies →1 of the 14 studies in Hyperuricemia with a site in Taiwan is open now. Recruiting first, the newest first:
Intelligem Therapeutics Australia Pty Ltd. · Sites in Taiwan, Australia
Ages 18–75
A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →
Of the 29 Hyperuricemia studies recruiting now, 8 (28%) set no upper age limit and 13 (45%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 5 · Phase 3 2 · Phase 4 1
First in 2004; this study’s year is marked. 2 started in 2013.
This study's enrollment of 82 is above the median of 68 across 193 interventional studies indexed under Hyperuricemia.
Median enrollment 120 across the 9 interventional studies, 210 across the 3 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 14 have an industry lead sponsor. The 9 most frequent:
TWi Biotechnology, Inc. is the lead sponsor of 11 studies on the registry; none are open to participants now.
TWi Biotechnology, Inc. has 1 study filed under Hyperuricemia — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hyperuricemia with a site in Taiwan, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Initiation of ULT for gout increases the occurrence of acute gouty arthritis flares due to mobilization of urate from tissue deposits. IL-1β plays a key role in mediating the inflammatory response in gouty arthritis. The efficacy of IL-1β blockade in the prophylaxis of gouty flares during initiation of ULT has been validated in multiple trials of IL-1β inhibitor therapies. Therefore, it is believed that IL-1β is a relevant therapeutic target for gout flares. AC-201 is an IL-1β modulator indicated for the treatment of osteoarthritis with good safety record and very few contraindications to the co-morbidities commonly among gout patients. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.
Clinical trials have demonstrated that anti-IL-1 agents (IL-1Ra, IL-1 Trap, and anti-IL-1β monoclonal antibody) can reduce the frequency of gout flares during the initial period of treatment with urate-lowering therapy and prevent of gout flares in gout patients with frequent flares. AC-201 is an oral IL-1 modulator but with a mechanism distinct from that of existing anti-IL-1 agents. The active metabolite of AC-201 has been shown in vitro and in vivo to inhibit the production and activity of IL-1, down-regulate IL-1 receptors, and increase IL1-Ra. Molecular research further suggests that these effects are mediated upstream via inhibition of MAPK signaling pathways and binding of NF-κB and AP-1 transcription factors that encode for a range of pro-inflammatory factors, including IL-1β, TNF-α, IL-6, IL-8, iNOS, and MMPs, which have been implicated in gout flares. AC-201 has also been demonstrated to have uric acid-lowering effects in clinical trials. The favorable product profile of AC-201 overall provides a strong rationale for investigating its clinical utility as prophylaxis against flares when initiating ULT.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo plus Febuxostat
Drug: Placebo · Drug: Febuxostat
AC-201 plus Febuxostat
Drug: AC-201 · Drug: Febuxostat
Placebo Capsule BID for 16 Weeks
Also known as: PBO
AC-201 50mg Capsule BID for 16 Weeks
Febuxostat 80 mg QD for 16 Weeks
Also known as: ULT
Number of Gout Flares Per Subject
Time frame: 16 weeks
Overall, 82 patients from 8 clinical centers participated in the study between 28 January 2013 to 04 September 2013.
| Milestone | Placebo | AC-201 |
|---|---|---|
| Started | 41 | 41 |
| Completed | 33 | 36 |
| Not completed | 8 | 5 |
| Withdrew: Adverse event | 3 | 1 |
| Withdrew: Withdrawal by subject | 3 | 3 |
| Withdrew: Lost to follow-up | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 |
| flares | Placebo | AC-201 |
|---|---|---|
| Number of Gout Flares Per Subject | 3.02 (2.51 to 3.64) | 2.45 (2.01 to 3.00) |
Collected over 16 weeks. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 1/41 (2.4%) | 11/41 (26.8%) |
| AC-201 | — | 0/41 (0%) | 10/41 (24.4%) |
| Event | Placebo | AC-201 |
|---|---|---|
| Frequent Gout AttackMetabolism and nutrition disorders | 1/41 | 0/41 |
| Event | Placebo | AC-201 |
|---|---|---|
| Blood CPK increasedInvestigations | 4/41 | 1/41 |
| Hepatic function abnormalHepatobiliary disorders | 3/41 | 2/41 |
| ALT increasedInvestigations | 3/41 | 0/41 |
| TendonitisMusculoskeletal and connective tissue disorders | 1/41 | 2/41 |
| Renal ImpairmentRenal and urinary disorders | 1/41 | 2/41 |
| AnemiaBlood and lymphatic system disorders | 0/41 | 2/41 |
| NasopharyngitisInfections and infestations | 0/41 | 2/41 |
| Creatinine renal clearance decreasedInvestigations | 0/41 | 2/41 |
A total of 82 subjects were randomized and received at least one dose of study medication (the Intent-to-Treat \[ITT\] Population). The ITT Population was used for baseline/demographic, disposition, and safety summaries. The ITT Population was the primary analysis set for efficacy analyses.
| Age, Continuous(years) | Placebo Capsule BID | AC-201 50mg Capsule BID | Total |
|---|---|---|---|
| Mean | 43.6 ± 11.8 | 43.7 ± 12.6 | 43.6 ± 12.1 |
| Sex: Female, Male(Participants) | Placebo Capsule BID | AC-201 50mg Capsule BID | Total |
|---|---|---|---|
| Female | 0 | 0 | 0 |
| Male | 41 | 41 | 82 |
The record gives a start of Jan 2013, a primary completion of Sep 2013 and a completion of Sep 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Dec 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Diacerein
TWi Biotechnology, Inc.